The skeletal impact of cancer therapies

Lucia Bedatsova, Matthew M Drake

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Both cancer and therapies used in the treatment of cancer can have significant deleterious effects on the skeleton, increasing the risks for both bone loss and fracture development. While advancements in cancer therapies have resulted in enhanced cancer survivorship for patients with many types of malignancies, it is increasingly recognized that efforts to reduce bone loss and limit fractures must be considered for nearly all patients undergoing cancer therapy in order to diminish the anticipated future skeletal consequences. To date, most studies examining the impact of cancer therapies on skeletal outcomes have focused on endocrine-associated cancers of the breast and prostate, with more recent advances in our understanding of bone loss and fracture risk in other malignancies. Pharmacologic efforts to limit the adverse effects of cancer therapies on bone have nearly universally employed anti-resorptive approaches, although studies have frequently relied on surrogate outcomes such as changes in bone mineral density or bone turnover markers, rather than on fractures or other skeletal-related events, as primary study endpoints. Compounding current deficiencies for the provision of optimal care is the recognition that despite clearly written and straightforward society-based guidelines, vulnerable eligible patients are very often neither identified nor provided with appropriate treatments to limit the skeletal impact of their cancer therapies.

Original languageEnglish (US)
Pages (from-to)1161-1168
Number of pages8
JournalBritish Journal of Clinical Pharmacology
Volume85
Issue number6
DOIs
StatePublished - Jun 1 2019
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
Bone Fractures
Bone and Bones
Endocrine Gland Neoplasms
Bone Remodeling
Skeleton
Bone Density
Prostatic Neoplasms
Survival Rate
Guidelines
Breast Neoplasms

Keywords

  • androgen deprivation therapy
  • aromatase inhibitor
  • bone loss
  • breast cancer
  • myeloma
  • prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The skeletal impact of cancer therapies. / Bedatsova, Lucia; Drake, Matthew M.

In: British Journal of Clinical Pharmacology, Vol. 85, No. 6, 01.06.2019, p. 1161-1168.

Research output: Contribution to journalReview article

@article{9334697d62d5488ca50cf98bc63c24a0,
title = "The skeletal impact of cancer therapies",
abstract = "Both cancer and therapies used in the treatment of cancer can have significant deleterious effects on the skeleton, increasing the risks for both bone loss and fracture development. While advancements in cancer therapies have resulted in enhanced cancer survivorship for patients with many types of malignancies, it is increasingly recognized that efforts to reduce bone loss and limit fractures must be considered for nearly all patients undergoing cancer therapy in order to diminish the anticipated future skeletal consequences. To date, most studies examining the impact of cancer therapies on skeletal outcomes have focused on endocrine-associated cancers of the breast and prostate, with more recent advances in our understanding of bone loss and fracture risk in other malignancies. Pharmacologic efforts to limit the adverse effects of cancer therapies on bone have nearly universally employed anti-resorptive approaches, although studies have frequently relied on surrogate outcomes such as changes in bone mineral density or bone turnover markers, rather than on fractures or other skeletal-related events, as primary study endpoints. Compounding current deficiencies for the provision of optimal care is the recognition that despite clearly written and straightforward society-based guidelines, vulnerable eligible patients are very often neither identified nor provided with appropriate treatments to limit the skeletal impact of their cancer therapies.",
keywords = "androgen deprivation therapy, aromatase inhibitor, bone loss, breast cancer, myeloma, prostate cancer",
author = "Lucia Bedatsova and Drake, {Matthew M}",
year = "2019",
month = "6",
day = "1",
doi = "10.1111/bcp.13866",
language = "English (US)",
volume = "85",
pages = "1161--1168",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The skeletal impact of cancer therapies

AU - Bedatsova, Lucia

AU - Drake, Matthew M

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Both cancer and therapies used in the treatment of cancer can have significant deleterious effects on the skeleton, increasing the risks for both bone loss and fracture development. While advancements in cancer therapies have resulted in enhanced cancer survivorship for patients with many types of malignancies, it is increasingly recognized that efforts to reduce bone loss and limit fractures must be considered for nearly all patients undergoing cancer therapy in order to diminish the anticipated future skeletal consequences. To date, most studies examining the impact of cancer therapies on skeletal outcomes have focused on endocrine-associated cancers of the breast and prostate, with more recent advances in our understanding of bone loss and fracture risk in other malignancies. Pharmacologic efforts to limit the adverse effects of cancer therapies on bone have nearly universally employed anti-resorptive approaches, although studies have frequently relied on surrogate outcomes such as changes in bone mineral density or bone turnover markers, rather than on fractures or other skeletal-related events, as primary study endpoints. Compounding current deficiencies for the provision of optimal care is the recognition that despite clearly written and straightforward society-based guidelines, vulnerable eligible patients are very often neither identified nor provided with appropriate treatments to limit the skeletal impact of their cancer therapies.

AB - Both cancer and therapies used in the treatment of cancer can have significant deleterious effects on the skeleton, increasing the risks for both bone loss and fracture development. While advancements in cancer therapies have resulted in enhanced cancer survivorship for patients with many types of malignancies, it is increasingly recognized that efforts to reduce bone loss and limit fractures must be considered for nearly all patients undergoing cancer therapy in order to diminish the anticipated future skeletal consequences. To date, most studies examining the impact of cancer therapies on skeletal outcomes have focused on endocrine-associated cancers of the breast and prostate, with more recent advances in our understanding of bone loss and fracture risk in other malignancies. Pharmacologic efforts to limit the adverse effects of cancer therapies on bone have nearly universally employed anti-resorptive approaches, although studies have frequently relied on surrogate outcomes such as changes in bone mineral density or bone turnover markers, rather than on fractures or other skeletal-related events, as primary study endpoints. Compounding current deficiencies for the provision of optimal care is the recognition that despite clearly written and straightforward society-based guidelines, vulnerable eligible patients are very often neither identified nor provided with appropriate treatments to limit the skeletal impact of their cancer therapies.

KW - androgen deprivation therapy

KW - aromatase inhibitor

KW - bone loss

KW - breast cancer

KW - myeloma

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85063957635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063957635&partnerID=8YFLogxK

U2 - 10.1111/bcp.13866

DO - 10.1111/bcp.13866

M3 - Review article

C2 - 30723928

AN - SCOPUS:85063957635

VL - 85

SP - 1161

EP - 1168

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 6

ER -